Global Pancreatic Cancer Opportunity Analysis and Forecasts Report 2020: Market Expected to Grow at 11.5% CAGR to $5.4B During 2019-2029
January 06, 2021 11:03 ET | Research and Markets
Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Pancreatic cancer is...
PMCB YT .png
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
PMCB YT .png
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
January 23, 2019 09:25 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
May 21, 2018 09:20 ET | PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
September 30, 2015 09:30 ET | PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
March 18, 2015 09:00 ET | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
December 16, 2013 09:15 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer
September 11, 2013 08:45 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 11, 2013) - Nuvilex, Inc. (OTCQB: NVLX) and its shareholders enjoyed what could be a dress rehearsal of their own future with the Food and Drug Administration's...